studies

mML - L2 - all population, Ipilimumab (10 mg/kg) vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsAscierto (ipi 10 vs 3 mg/kg), 2017 0.84 [0.71; 1.00] 0.84[0.71; 1.00]Ascierto (ipi 10 vs 3 mg/kg), 201710%727NAnot evaluable progression or deaths (PFS)detailed resultsAscierto (ipi 10 vs 3 mg/kg), 2017 0.89 [0.66; 1.21] 0.89[0.66; 1.21]Ascierto (ipi 10 vs 3 mg/kg), 201710%727NAnot evaluable DCRdetailed resultsAscierto (ipi 10 vs 3 mg/kg), 2017 1.19 [0.86; 1.63] 1.19[0.86; 1.63]Ascierto (ipi 10 vs 3 mg/kg), 201710%727NAnot evaluable objective responses (ORR)detailed resultsAscierto (ipi 10 vs 3 mg/kg), 2017 1.31 [0.86; 2.00] 1.31[0.86; 2.00]Ascierto (ipi 10 vs 3 mg/kg), 201710%727NAnot evaluable TRAE (any grade)detailed resultsAscierto (ipi 10 vs 3 mg/kg), 2017 2.40 [1.76; 3.28] 2.40[1.76; 3.28]Ascierto (ipi 10 vs 3 mg/kg), 201710%726NAnot evaluable TRAE (grade 3-4)detailed resultsAscierto (ipi 10 vs 3 mg/kg), 2017 2.70 [1.86; 3.92] 2.70[1.86; 3.92]Ascierto (ipi 10 vs 3 mg/kg), 201710%726NAnot evaluable TRAE leading to death (grade 5)detailed resultsAscierto (ipi 10 vs 3 mg/kg), 2017 2.00 [0.36; 10.99] 2.00[0.36; 10.99]Ascierto (ipi 10 vs 3 mg/kg), 201710%726NAnot evaluable TRAE leading to discontinuation (any grade)detailed resultsAscierto (ipi 10 vs 3 mg/kg), 2017 1.97 [1.40; 2.78] 1.97[1.40; 2.78]Ascierto (ipi 10 vs 3 mg/kg), 201710%726NAnot evaluable TRAE leading to discontinuation (grade 3-4)detailed resultsAscierto (ipi 10 vs 3 mg/kg), 2017 2.27 [1.53; 3.38] 2.27[1.53; 3.38]Ascierto (ipi 10 vs 3 mg/kg), 201710%726NAnot evaluable Adrenal insufficiency TRAE (grade 3-4)detailed resultsAscierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56] 1.99[0.07; 59.56]Ascierto (ipi 10 vs 3 mg/kg), 201710%726NAnot evaluable Colitis TRAE (grade 3-4)detailed resultsAscierto (ipi 10 vs 3 mg/kg), 2017 2.16 [0.96; 4.84] 2.16[0.96; 4.84]Ascierto (ipi 10 vs 3 mg/kg), 201710%726NAnot evaluable Diarrhoea TRAE (grade 3-4)detailed resultsAscierto (ipi 10 vs 3 mg/kg), 2017 1.84 [1.05; 3.21] 1.84[1.05; 3.21]Ascierto (ipi 10 vs 3 mg/kg), 201710%726NAnot evaluable Endocrine disorders TRAE (grade 3-4) detailed resultsAscierto (ipi 10 vs 3 mg/kg), 2017 2.30 [0.99; 5.36] 2.30[0.99; 5.36]Ascierto (ipi 10 vs 3 mg/kg), 201710%726NAnot evaluable Eye disorders TRAE (grade 3-4)detailed resultsAscierto (ipi 10 vs 3 mg/kg), 2017 0.50 [0.02; 14.85] 0.50[0.02; 14.85]Ascierto (ipi 10 vs 3 mg/kg), 201710%726NAnot evaluable Febrile neutropenia TRAE (grade 3-4)detailed resultsAscierto (ipi 10 vs 3 mg/kg), 2017 3.99 [0.18; 88.89] 3.99[0.18; 88.89]Ascierto (ipi 10 vs 3 mg/kg), 201710%726NAnot evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed resultsAscierto (ipi 10 vs 3 mg/kg), 2017 1.82 [1.14; 2.91] 1.82[1.14; 2.91]Ascierto (ipi 10 vs 3 mg/kg), 201710%726NAnot evaluable Guillain-Barré syndrome TRAE (grade 3-4)detailed resultsAscierto (ipi 10 vs 3 mg/kg), 2017 3.99 [0.18; 88.89] 3.99[0.18; 88.89]Ascierto (ipi 10 vs 3 mg/kg), 201710%726NAnot evaluable Hepatitis TRAE (grade 3-4)detailed resultsAscierto (ipi 10 vs 3 mg/kg), 2017 2.51 [0.48; 13.01] 2.51[0.48; 13.01]Ascierto (ipi 10 vs 3 mg/kg), 201710%726NAnot evaluable Hypersensitivity TRAE (grade 3-4)detailed resultsAscierto (ipi 10 vs 3 mg/kg), 2017 6.01 [0.30; 120.38] 6.01[0.30; 120.38]Ascierto (ipi 10 vs 3 mg/kg), 201710%726NAnot evaluable Hypophysitis TRAE (grade 3-4)detailed resultsAscierto (ipi 10 vs 3 mg/kg), 2017 1.43 [0.54; 3.81] 1.43[0.54; 3.81]Ascierto (ipi 10 vs 3 mg/kg), 201710%726NAnot evaluable Hypothyroidism TRAE (grade 3-4)detailed resultsAscierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56] 1.99[0.07; 59.56]Ascierto (ipi 10 vs 3 mg/kg), 201710%726NAnot evaluable Increase AST TRAE (grade 3-4)detailed resultsAscierto (ipi 10 vs 3 mg/kg), 2017 8.11 [1.01; 65.20] 8.11[1.01; 65.20]Ascierto (ipi 10 vs 3 mg/kg), 201710%726NAnot evaluable Increased ALT TRAE (grade 3-4)detailed resultsAscierto (ipi 10 vs 3 mg/kg), 2017 6.14 [1.36; 27.62] 6.14[1.36; 27.62]Ascierto (ipi 10 vs 3 mg/kg), 201710%726NAnot evaluable Increased lipase level TRAE (grade 3-4)detailed resultsAscierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56] 1.99[0.07; 59.56]Ascierto (ipi 10 vs 3 mg/kg), 201710%726NAnot evaluable Infusion-related reactions TRAE (grade 3-4)detailed resultsAscierto (ipi 10 vs 3 mg/kg), 2017 3.99 [0.18; 88.89] 3.99[0.18; 88.89]Ascierto (ipi 10 vs 3 mg/kg), 201710%726NAnot evaluable Maculopapular rash TRAE (grade 3-4)detailed resultsAscierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56] 1.99[0.07; 59.56]Ascierto (ipi 10 vs 3 mg/kg), 201710%726NAnot evaluable Nervous system disorders TRAE (grade 3-4)detailed resultsAscierto (ipi 10 vs 3 mg/kg), 2017 8.03 [0.42; 152.51] 8.03[0.42; 152.51]Ascierto (ipi 10 vs 3 mg/kg), 201710%726NAnot evaluable Pancreatitis TRAE (grade 3-4)detailed resultsAscierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56] 1.99[0.07; 59.56]Ascierto (ipi 10 vs 3 mg/kg), 201710%726NAnot evaluable Pancytopenia TRAE (grade 3-4)detailed resultsAscierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56] 1.99[0.07; 59.56]Ascierto (ipi 10 vs 3 mg/kg), 201710%726NAnot evaluable Pericarditis TRAE (grade 3-4)detailed resultsAscierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56] 1.99[0.07; 59.56]Ascierto (ipi 10 vs 3 mg/kg), 201710%726NAnot evaluable Peripheral neuropathy TRAE (grade 3-4)detailed resultsAscierto (ipi 10 vs 3 mg/kg), 2017 3.99 [0.18; 88.89] 3.99[0.18; 88.89]Ascierto (ipi 10 vs 3 mg/kg), 201710%726NAnot evaluable Pneumonitis TRAE (grade 3-4)detailed resultsAscierto (ipi 10 vs 3 mg/kg), 2017 8.03 [0.42; 152.51] 8.03[0.42; 152.51]Ascierto (ipi 10 vs 3 mg/kg), 201710%726NAnot evaluable Polymyalgia Rheumatica TRAE (grade 3-4)detailed resultsAscierto (ipi 10 vs 3 mg/kg), 2017 0.50 [0.02; 14.85] 0.50[0.02; 14.85]Ascierto (ipi 10 vs 3 mg/kg), 201710%726NAnot evaluable Pruritic rash TRAE (grade 3-4)detailed resultsAscierto (ipi 10 vs 3 mg/kg), 2017 0.50 [0.02; 14.85] 0.50[0.02; 14.85]Ascierto (ipi 10 vs 3 mg/kg), 201710%726NAnot evaluable Pruritus TRAE (grade 3-4)detailed resultsAscierto (ipi 10 vs 3 mg/kg), 2017 0.99 [0.14; 7.10] 0.99[0.14; 7.10]Ascierto (ipi 10 vs 3 mg/kg), 201710%726NAnot evaluable Rash TRAE (grade 3-4)detailed resultsAscierto (ipi 10 vs 3 mg/kg), 2017 2.51 [0.48; 13.01] 2.51[0.48; 13.01]Ascierto (ipi 10 vs 3 mg/kg), 201710%726NAnot evaluable Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) detailed resultsAscierto (ipi 10 vs 3 mg/kg), 2017 8.03 [0.42; 152.51] 8.03[0.42; 152.51]Ascierto (ipi 10 vs 3 mg/kg), 201710%726NAnot evaluable Skin and subcutaneous tissue disorders TRAE (grade 3-4) detailed resultsAscierto (ipi 10 vs 3 mg/kg), 2017 1.40 [0.44; 4.45] 1.40[0.44; 4.45]Ascierto (ipi 10 vs 3 mg/kg), 201710%726NAnot evaluable Thyroiditis TRAE (grade 3-4)detailed resultsAscierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56] 1.99[0.07; 59.56]Ascierto (ipi 10 vs 3 mg/kg), 201710%726NAnot evaluable Uveitis TRAE (grade 3-4)detailed resultsAscierto (ipi 10 vs 3 mg/kg), 2017 0.50 [0.02; 14.85] 0.50[0.02; 14.85]Ascierto (ipi 10 vs 3 mg/kg), 201710%726NAnot evaluable0.220.01.0relative treatment effectwww.metaEvidence.org2024-06-01 14:17 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 69 - treatments: 558

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons